FI3389699T3 - Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja - Google Patents
Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja Download PDFInfo
- Publication number
- FI3389699T3 FI3389699T3 FIEP16876612.9T FI16876612T FI3389699T3 FI 3389699 T3 FI3389699 T3 FI 3389699T3 FI 16876612 T FI16876612 T FI 16876612T FI 3389699 T3 FI3389699 T3 FI 3389699T3
- Authority
- FI
- Finland
- Prior art keywords
- chimeric
- antibodies
- seq
- human monoclonal
- ctla4 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267735P | 2015-12-15 | 2015-12-15 | |
| US201662309169P | 2016-03-16 | 2016-03-16 | |
| US201662359036P | 2016-07-06 | 2016-07-06 | |
| PCT/US2016/066698 WO2017106372A1 (en) | 2015-12-15 | 2016-12-14 | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3389699T3 true FI3389699T3 (fi) | 2024-05-28 |
Family
ID=59057509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16876612.9T FI3389699T3 (fi) | 2015-12-15 | 2016-12-14 | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10618960B2 (enExample) |
| EP (2) | EP4374926A3 (enExample) |
| JP (5) | JP6858779B2 (enExample) |
| KR (2) | KR102830926B1 (enExample) |
| CN (2) | CN108430499B (enExample) |
| AU (3) | AU2016370648B2 (enExample) |
| BR (1) | BR112018012113A2 (enExample) |
| CA (1) | CA3006984C (enExample) |
| DK (1) | DK3389699T5 (enExample) |
| ES (1) | ES2979210T3 (enExample) |
| FI (1) | FI3389699T3 (enExample) |
| HR (1) | HRP20240719T1 (enExample) |
| HU (1) | HUE066907T2 (enExample) |
| IL (3) | IL259988B2 (enExample) |
| LT (1) | LT3389699T (enExample) |
| MX (3) | MX2018006925A (enExample) |
| MY (1) | MY186974A (enExample) |
| PL (1) | PL3389699T3 (enExample) |
| PT (1) | PT3389699T (enExample) |
| RS (1) | RS65703B1 (enExample) |
| SG (1) | SG11201804969PA (enExample) |
| SI (1) | SI3389699T1 (enExample) |
| SM (1) | SMT202400211T1 (enExample) |
| TW (1) | TWI739781B (enExample) |
| WO (1) | WO2017106372A1 (enExample) |
| ZA (1) | ZA201804077B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| AU2018366199A1 (en) * | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| AU2019214865B2 (en) * | 2018-02-02 | 2025-04-10 | OncoC4, Inc. | Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| EP3746122A4 (en) * | 2018-02-02 | 2021-11-24 | OncoC4, Inc. | SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| CN112399973B (zh) | 2018-06-05 | 2022-12-16 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CN114008071B (zh) * | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| KR20220166795A (ko) * | 2020-04-13 | 2022-12-19 | 바이오션, 인코포레이티드 | Ctla4에 결합하는 항체 및 이의 용도 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| KR20220112208A (ko) * | 2021-02-03 | 2022-08-10 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2022214653A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
| JP7345889B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| AU2022361768A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| CN118176021A (zh) | 2021-10-29 | 2024-06-11 | 昂科医药 | 抗ctla-4抗体给药方案 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024059833A1 (en) | 2022-09-16 | 2024-03-21 | OncoC4, Inc. | Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| MX2025012859A (es) | 2023-04-28 | 2026-02-03 | Oncoc4 Inc | Combinaciones de anticuerpos anti-ctla-4 y anticuerpos anti-pd-1 y usos terapeuticos de los mismos |
| EP4724498A2 (en) * | 2023-06-09 | 2026-04-15 | The Regents of the University of California | Methods for identifying and correcting tumor humoral immune dysfunction |
| WO2025133186A1 (en) | 2023-12-22 | 2025-06-26 | OncoC4, Inc. | Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| WO2025234450A1 (ja) * | 2024-05-08 | 2025-11-13 | 学校法人帝京平成大学 | 改変がん細胞及びそれを含むがんワクチン組成物 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026041780A2 (en) | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
| WO2026057739A1 (en) | 2024-09-12 | 2026-03-19 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| EP1234031B2 (en) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| WO2006029220A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Combination therapy with anti-ctla4 and anti-4-1bb antibodies |
| CN101076807B (zh) | 2004-10-15 | 2014-09-03 | 弗里塞恩公司 | 一次性密码验证的方法和系统 |
| CN101146826A (zh) * | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| HRP20200744T1 (hr) * | 2011-12-22 | 2020-07-24 | F. Hoffmann - La Roche Ag | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida |
| WO2013142796A2 (en) * | 2012-03-23 | 2013-09-26 | Bristol-Myers Squibb Company | Methods of treatments using ctla4 antibodies |
| EP2925350B1 (en) * | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
-
2016
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 KR KR1020187017368A patent/KR102830926B1/ko active Active
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 BR BR112018012113-4A patent/BR112018012113A2/en active Search and Examination
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 SM SM20240211T patent/SMT202400211T1/it unknown
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en not_active Ceased
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 CN CN202210802423.XA patent/CN116063492A/zh active Pending
- 2016-12-14 KR KR1020257022200A patent/KR20250108763A/ko active Pending
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
-
2018
- 2018-06-07 MX MX2025001302A patent/MX2025001302A/es unknown
- 2018-06-07 MX MX2025001300A patent/MX2025001300A/es unknown
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
-
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
-
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
-
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
-
2023
- 2023-03-22 US US18/188,098 patent/US12473362B2/en active Active
- 2023-05-19 AU AU2023203169A patent/AU2023203169B2/en active Active
- 2023-05-24 JP JP2023085801A patent/JP7790837B2/ja active Active
-
2025
- 2025-08-04 JP JP2025130097A patent/JP2025160458A/ja active Pending
-
2026
- 2026-02-05 AU AU2026200849A patent/AU2026200849A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| FI4050034T3 (fi) | Cd3:een sitoutuvia vasta-aineita | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| ZA202001251B (en) | Interleukin-21 muteins and methods of treatment | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| FI3303396T3 (fi) | Vasta-aineita ox40:ää vastaan ja niiden käyttöjä | |
| RU2017105120A (ru) | Cd3-связывающий домен | |
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| JP2018508483A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
| JP2014502955A5 (enExample) | ||
| EA034770B8 (ru) | Человеческие антитела к pd-1 | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc |